Heartflow Reports 40% Revenue Growth Amidst $116.8M Loss, DOJ Probe, and Potential Medicare Reimbursement Cut

summarizeSummary

Heartflow, Inc. reported 40% revenue growth to $176.0 million for 2025 but incurred a net loss of $116.8 million, increasing its accumulated deficit to $1.1 billion. The company disclosed an ongoing DOJ investigation and a proposed 15% Medicare reimbursement cut for its core product, while also highlighting new product launches and successful IPO proceeds.

check_boxKey Events

• Significant Net Loss and Accumulated Deficit

  The company reported a net loss of $116.8 million for the fiscal year ended December 31, 2025, contributing to an accumulated deficit of $1.1 billion.

• Strong Revenue Growth

  Revenue increased by 40% to $176.0 million in 2025, up from $125.8 million in 2024, driven by a 47% increase in revenue case volume.

• DOJ Civil Investigation Disclosed

  Heartflow, Inc. and certain employees received a Civil Investigative Demand in October 2025 from the U.S. Department of Justice, investigating potential violations of the federal Anti-Kickback Statute and Civil False Claims Act. The company is cooperating but cannot predict the duration or material financial impact.

• Potential Medicare Reimbursement Rate Reduction

  CMS has proposed a 2026 rule that could result in a reduction of up to 15% in the Medicare reimbursement rate for Heartflow FFRct Analysis, which currently represents 98% of the company's total revenue.

auto_awesomeAnalysis

Heartflow, Inc.'s annual report reveals a mixed financial picture with strong revenue growth offset by significant losses and critical legal and reimbursement risks. While the 40% revenue increase and successful IPO provide a positive signal for market adoption and liquidity, the substantial net loss and accumulated deficit highlight ongoing profitability challenges. The disclosure of a Civil Investigative Demand from the U.S. Department of Justice, investigating potential Anti-Kickback Statute and Civil False Claims Act violations, introduces significant uncertainty and potential material financial impact. Furthermore, the proposed 15% reduction in Medicare reimbursement rates for Heartflow FFRct Analysis, which accounts for 98% of the company's revenue, poses a direct and severe threat to its primary income stream. Investors should closely monitor developments in the DOJ investigation and the finalization of Medicare reimbursement rates, as these events could materially alter the company's financial trajectory and investment thesis.